Feasibility of Suprapubic Transvesical Endoscopic Prostatectomy

NCT07327424 | Active Not Recruiting

• 1 other identifier: FMBSUREC/01072025/Mohamed
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

In patients with penile prosthesis, any transurethral procedure could place the implant at risk. The use of long or extra-long resectoscope can be of some assistance; however, these are not available in many institutions. So suprapubic transvesical endoscopic prostatectomy is newly developed to bypass the anterior urethra. Thus, the aim of this study is to determine safety and efficacy of Suprapubic Transvesical endoscopic prostatectomy.

Conditions

Prostate

Outcome Measures

Primary Outcomes (1)

• International Prostate Symptom Score

  6 months

Secondary Outcomes (2)

• Q max

  6 months

• PVR (post-void residual volume)

  6 MONTHS

Study Arms (1)

Suprapubic Transvesical endoscopic prostatectomy

EXPERIMENTAL

Other: Suprapubic transvesical endoscopic prostatectomy

Interventions

Suprapubic transvesical endoscopic prostatectomy OTHER

Cysto-uretheroscopy will be done to evaluate the urethera , detect any bladder pathology and to visualise steps of insertion of laparoscopic port. The patient will be in supine position, and the surgeon will stand beside the patient .The bladder is filled with normal saline until it is completely full . Using Ultrasound A 18 G puncture needle is inserted 4 cm above the upper margin of the symphysis pubis to gain access to the bladder. then track is formed through single step dilation using a 30 Fr amplatz dilator and 10 mm laparoscopic port over it. Before starting the procedure, the ureteral orifices must be identified.

Suprapubic Transvesical endoscopic prostatectomy

Eligibility Criteria

• Age: 55 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male patients with moderate to severe lower urinary tract symptoms ( IPSS score ≥ 8 ) indicated for surgical intervention with prostate size less than 120 cc.

You may not qualify if:

• History of previous pelvic surgery, urothelial cancer, kidney transplantation, uncontrolled coagulopathy, and significant central fat accumulation that could potentially increase the risk during transvesical access(body mass index not exceeding 27 kg/m2)

Sponsors & Collaborators

• Beni-Suef University: lead

Study Sites (1)

Beni-Suef university

Banī Suwayf, Egypt

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Ahmed Abdelbary

Study Record Dates

• First Submitted: December 25, 2025
• First Posted: January 8, 2026
• Study Start: July 15, 2025
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): June 1, 2027
• Last Updated: January 8, 2026

Record last verified: 2025-12

Locations

EG (1)